• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20001 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2000     Institute for Clinical Systems Improvement (ICSI) Transmyocardial laser therapy for severe refractory angina
1998     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Transmyocardial revascularisation by laser (systematic review, expert panel)
1998     University HealthSystem Consortium (UHC) Transmyocardial revascularization
2002     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Transmyocardial revascularization for treatment of angina
1996     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) Transmyocardial revascularization with laser
2011     Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS) Transnasal oesophagoscopy (TNE)
1998     Institute of Technology Assessment (ITA) Transnational analysis of the socio-economic impact of Alzheimer's disease (AD) in the European Union
2005     National Institute for Clinical Excellence (NICE) Transobturator foramen procedures for stress urinary incontinence
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Transobturator slings for urinary incontinence: clinical effectiveness and guidelines
2002     Medical Services Advisory Committee (MSAC) Transoesophageal echocardiography
2015     Canadian Agency for Drugs and Technologies in Health (CADTH) Transoral robotic surgery: a review of clinical and cost-effectiveness
2022     Norwegian Institute of Public Health (NIPH) Transperineal compared with transrectal biopsy on suspected prostate cancer: a health technology assessment
2010     National Institute for Health and Clinical Excellence (NICE) Transperineal template biopsy of the prostate
2002     HAYES, Inc. Transperineal ultrasound-guided brachytherapy for early-stage prostate cancer
2005     Technology Assessment Unit of the McGill University Health Centre (MUHC) Transplantation of allogeneic hematopoietic stem cells from unrelated donors in adult patients at the MUHC
2003     The Swedish Council on Health Technology Assessment (SBU) Transplantation of cultured skin (Apligraf(R)) in treating venous leg ulcers - early assessment briefs (Alert)
2001     The Swedish Council on Health Technology Assessment (SBU) Transplantation of stem cells from umbilical cord blood - early assessment briefs (Alert)
1994     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Transplantation with bone marrow not derived from HLA identical family donors for the treatment of adults and children with hemato-oncologic and congenital diseases - primary research
2002     Blue Cross Blue Shield Association (BCBS) Transplanting adult patients with hematopoietic stem cells from placental and umbilical cord blood
2006     National Institute for Clinical Excellence (NICE) Transport interventions promoting safe cycling and walking: evidence briefing
2012     NIHR Horizon Scanning Centre (NIHR HSC) Transportable haemodialysis machines for established renal failure
2007     New Zealand Health Technology Assessment (NZHTA) Transportation of emergency patients
2003     Institute for Clinical Effectiveness and Health Policy (IECS) Transpupillary thermotherapy
2004     National Institute for Clinical Excellence (NICE) Transpupillary thermotherapy for age-related macular degeneration
2002     NIHR Horizon Scanning Centre (NIHR HSC) Transpupillary thermotherapy for age-related macular degeneration - horizon scanning review
2002     HAYES, Inc. Transpupillary thermotherapy for choroidal tumors and macular degeneration
2011     Center for Evidence-based Practice (CEP) Transradial access for cardiac catheterization
2013     HAYES, Inc. Transradial, transbrachial, and transulnar approaches for coronary angiography and intervention
1994     Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS) Transurethral diathermy for benign prostatic hypertrophy: update -nonsystematic review
2003     National Institute for Clinical Excellence (NICE) Transurethral electrovaporisation of the prostate
2012     Medical Services Advisory Committee (MSAC) Transurethral injection of botulinum toxin into the ladder wall for urinary incontinence due to neurogenic detrusor overactivity
2000     HAYES, Inc. Transurethral microwave thermotherapy
2007     HAYES, Inc. Transurethral microwave thermotherapy
2000     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia
2002     Medical Services Advisory Committee (MSAC) TransUrethral Needle Ablation (TUNA) for the treatment of benign prostatic hyperplasia
2005     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) Transurethral needle ablation (TUNA) in the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis
2001     ECRI Transurethral needle ablation [TUNA (R)] for benign prostatic hyperplasia
2001     HAYES, Inc. Transurethral needle ablation therapy
2007     HAYES, Inc. Transurethral radiofrequency micro-remodeling using the Renessa system (Novasys Medical Inc.) for female stress urinary incontinence
2010     HAYES, Inc. Transurethral Radiofrequency Micro-Remodeling Using the Renessa System (Novasys Medical Inc.) for Female Stress Urinary Incontinence
2003     National Institute for Clinical Excellence (NICE) Transurethral radiofrequency needle ablation of the prostate
2011     HAYES, Inc. Transvaginal ultrasound for measurement of cervical length to predict preterm birth
2016     NIHR Health Technology Assessment programme TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer
2004     HAYES, Inc. Trastuzumab (Herceptin (R)) for breast cancer
2007     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab (Herceptin) for advanced gastric cancer
2007     HAYES, Inc. Trastuzumab (Herceptin) for early breast cancer
2012     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab (Herceptin) for HER2 positive early breast cancer – two year regimen
2010     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer - neoadjuvant treatment
2001     The Swedish Council on Health Technology Assessment (SBU) Trastuzumab (Herceptin) for metastasized breast cancer - early assessment briefs (Alert)
2007     HAYES, Inc. Trastuzumab (Herceptin) for metastatic cancer
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Trastuzumab (Herceptin) in addition to standard chemotherapy as first-line therapy for advanced gastric cancer
2006     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab (Herceptin) in combination with aromatase inhibitors for stage IV - metastatic breast cancer: horizon scanning technology briefing
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Trastuzumab (Herceptin®)
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Trastuzumab (Herceptin®) 150 mg powder for concentrate for solution for infusion
2003     ECRI Trastuzumab [Herceptin (R)] for the treatment of breast cancer
2005     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab as adjuvant therapy for early stage breast cancer - horizon scanning review
2013     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab emtansine (Kadcyla) for patients with HER2 positive locally advanced or metastatic relapsed gastric cancers
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Trastuzumab emtansine (KadcylaTM) for previously treated patients with HER2-positive advanced/metastatic breast cancer
2012     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab emtansine in combination with pertuzumab for HER2-positive metastatic breast cancer – first line
2005     Institute for Clinical Effectiveness and Health Policy (IECS) Trastuzumab for breast cancer treatment
2006     Quality Improvement Scotland (NHS QIS ) Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
2006     National Institute for Health and Clinical Excellence (NICE) Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
2011     NIHR Health Technology Assessment programme Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
2011     NIHR Health Technology Assessment programme Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
2010     National Institute for Health and Clinical Excellence (NICE) Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
2009     NIHR Health Technology Assessment programme Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal
2020     Agency for Care Effectiveness (ACE) Trastuzumab for treating HER2-positive breast and gastric cancers
2011     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab SC (Herceptin SC) for breast cancer, early or metastatic, HER2 positive - monotherapy or combination therapy, including neo-adjuvant and adjuvant use
2011     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab-DM1 (Herceptin-DM1) for breast cancer, locally advanced or metastatic, HER2 positive - second or third line
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Trastuzumab-emtansine (Kadcyla®) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage
2018     Canary Health Service Tratamiento nutricional de adultos con insuficiencia renal crónica (IRC) con desnutrición energético-proteica grave no reversible mediante alimentos de consumo ordinario
2011     Agency for Healthcare Research and Quality (AHRQ) Traumatic brain injury and depression.
2016     The Swedish Council on Health Technology Assessment (SBU) Traumatic shaking – The role of the triad in medical investigations of suspected traumatic shaking
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Travoprost (Travatan®)
2000     The Swedish Council on Health Technology Assessment (SBU) Treating asthma and COPD - a systematic review
1999     University of York Treating head lice and scabies
2001     The Swedish Council on Health Technology Assessment (SBU) Treating influenza by medication - zanamivir - early assessment briefs (ALERT)
2003     University of York Treating nocturnal enuresis in children
2003     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Treating osteoporosis with teriparatide: many unknowns?
2002     Norwegian Knowledge Centre for the Health Services (NOKC) Treating prostate cancer with brachytherapy
2011     Health Council of the Netherlands Gezondheidsraad (GR) Treating the effect of child abuse
2010     Institute of Health Economics (IHE) Treatment for convicted adult male sex offenders
2012     Agency for Healthcare Research and Quality (AHRQ) Treatment for depression after unsatisfactory response to SSRIs
2008     NIHR Health Technology Assessment programme Treatment for fibroids: Uterine Artery Embolisation (UAE) or hysterectomy (HOPEFUL) - Primary Research (e.g. trial)
2012     Agency for Healthcare Research and Quality (AHRQ) Treatment for glaucoma: comparative effectiveness
2012     Agency for Healthcare Research and Quality (AHRQ) Treatment for glaucoma: comparative effectiveness
2012     Agency for Healthcare Research and Quality (AHRQ) Treatment for hepatitis C virus infection in adults
2012     Agency for Healthcare Research and Quality (AHRQ) Treatment for restless legs syndrome
2018     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Treatment Foster Care Oregon for seriously delinquent adolescents
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of adult patients with immune thrombocytopenia after failure of first-line therapies
2022     NIHR Health Technology Assessment programme Treatment of Advanced Glaucoma Study (TAGS): a multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy for people with newly diagnosed advanced glaucoma
2001     L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Treatment of age related macular degeneration
2001     The Swedish Council on Health Technology Assessment (SBU) Treatment of alcohol and drug abuse - an evidence-based review
2012     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of anemia and neutropenia in patients with chronic hepatitis C infection treated with peginterferon-ribavirin based regimens with or without protease inhibitors: a review of the clinical evidence
2005     The Swedish Council on Health Technology Assessment (SBU) Treatment of anxiety disorders: a systematic review
2013     Agency for Healthcare Research and Quality (AHRQ) Treatment of atrial fibrillation
1999     Agency for Healthcare Research and Quality (AHRQ) Treatment of attention-deficit/hyperactivity disorder
1994     L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Treatment of autism
2022     NIHR Health Technology Assessment programme Treatment of Barth Syndrome by CARDIOlipin MANipulation (CARDIOMAN): a randomised placebo-controlled pilot trial conducted by the nationally commissioned Barth Syndrome Service
1995     Australian Health Technology Advisory Committee (AHTAC) Treatment of benign prostatic hyperplasia in Australia - some economic considerations